Company-reported prevalence

Ivonescimab

Overview

Field	Value
Drug	Ivonescimab (SMT112, AK112)
Indication	EGFR-mutated non-small-cell lung cancer
Disease	EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC); figures are also stated for all lung cancer and for NSCLC
Company	Summit Therapeutics Inc. (license territories: North America, South America, Europe, the Middle East, Africa, and Japan); Akeso, Inc. (originator and licensor; rest of world, including China)
Documents searched	Summit Therapeutics website pages: Ivonescimab Overview, Lung Cancer Overview, HARMONi Clinical Trial (accessed October 14, 2026); Summit Therapeutics press releases, January 2023 to September 2026 (company press release feed, full text); Summit Therapeutics Form 10-K for 2025 (filed February 2026); Summit Therapeutics presentations: WCLC update call (September 2025), ESMO update and Q3 2025 earnings call (October 2025), J.P. Morgan Healthcare Conference (January 2026), Q4 and full-year 2025 earnings call (February 2026), ASCO 2026 update call (June 2026); Akeso annual results announcement for 2025 (March 26, 2026); Akeso website home page (accessed October 14, 2026)
Data as of	October 14, 2026
Prepared by	AI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Eligible population: Summit Therapeutics press release, January 2026

“Over 14,000 U.S. Patients Eligible for Treatment Each Year in This Setting” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Summit Therapeutics (2026) press release, January 29, 2026, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Incidence (all lung cancer): Summit Therapeutics press release, August 2026

“In the United States, the American Cancer Society estimates that approximately 230,000 new lung cancer cases will be diagnosed and nearly 125,000 deaths from lung cancer will occur in 2026.” (opens the source at this quote in a new tab)

Cited source: 2.2 American Cancer Society 2026

Summit Therapeutics (2026) press release, August 25, 2026, quoted passage highlighted — Captured from page 3 of 8 (opens in a new tab)

Incidence (all lung cancer): Summit Therapeutics website, October 2026

“An estimated 234,000 people in the U.S. will be diagnosed with lung cancer in 2025 with a new diagnosis every 2.2 minutes.” (opens the source at this quote in a new tab)

Cited source: 2.7 LUNGevity Foundation 2025

Summit Therapeutics (2026) website, Lung Cancer Overview, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Incidence (all lung cancer): Summit Therapeutics press release, October 2023

“Lung cancer is believed to impact approximately 238,000” (opens the source at this quote in a new tab)
“people in the United States each year” (opens the source at this quote in a new tab)

Cited source: 2.2 American Cancer Society 2026

Summit Therapeutics (2023) press release, October 31, 2023, quoted passage highlighted — Captured from page 2 of 4 (opens in a new tab)

Europe

Incidence (all lung cancer in Europe): Summit Therapeutics press release, October 2023

“Lung cancer is believed to impact approximately 238,000” (opens the source at this quote in a new tab)
“people in the United States each year and approximately 477,000” (opens the source at this quote in a new tab)
“in Europe.” (opens the source at this quote in a new tab)

Cited source: 2.8 World Health Organization 2023

Global

Incidence (all lung cancer worldwide): Summit Therapeutics press release, August 2026

“Lung cancer is the second most commonly diagnosed cancer worldwide” (opens the source at this quote in a new tab)
“with an estimated 2.6 million new cases and 1.9 million deaths in 2024.” (opens the source at this quote in a new tab)

Cited source: 2.1 Sung 2026

Other countries and regions

Number affected (all lung cancer): Summit Therapeutics press release, August 2024

“Lung cancer is believed to impact approximately 600,000 people across the United States, United Kingdom, Spain, France, Italy, Germany, and Japan.” (opens the source at this quote in a new tab)

Cited source: 2.2 American Cancer Society 2026; 2.9 International Agency for Research on Cancer 2024; 2.10 Japan National Cancer Registry 2024

Summit Therapeutics (2024) press release, August 6, 2024, quoted passage highlighted — Captured from page 6 of 13 (opens in a new tab)

Prevalence (share of non-squamous NSCLC with EGFR-sensitizing mutations): Summit Therapeutics press release, August 2024

“Among patients with non-squamous NSCLC, approximately 15% have EGFR-sensitizing mutations in the United States and Europe.” (opens the source at this quote in a new tab)

Cited source: 2.6 LUNGevity Foundation 2024

Prevalence (share of non-squamous NSCLC with EGFR mutations): Summit Therapeutics press release, August 2026

“EGFR mutations are among the most common actionable oncogenic drivers in non-squamous NSCLC, occurring in approximately 10-15% of patients in western populations and 40-50% of patients in Asia.” (opens the source at this quote in a new tab)

Cited source: 2.4 National Cancer Institute 2025; 2.5 Midha 2015

Geography not stated

Prevalence (share of all lung cancer that is NSCLC): Summit Therapeutics press release, August 2026

“Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing approximately 80% to 85% of all cases.” (opens the source at this quote in a new tab)

Cited source: 2.1 Sung 2026; 2.3 American Cancer Society 2024

Prevalence (share of all lung cancer that is NSCLC): Summit Therapeutics website, October 2026

“Non-Small Cell Lung Cancer (NSCLC)” (opens the source at this quote in a new tab)
“Accounts for about 80% to 85% of all lung cancer cases” (opens the source at this quote in a new tab)

Cited source: 2.2 American Cancer Society 2026; 2.11 National Foundation for Cancer Research 2020

Sources the company cites

Sung 2026

Reference as the company lists it

“Sung H, Filho AM, Siegel RL, Laversanne M, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026. doi:10.3322/caac.70090.” (opens the source at this quote in a new tab)

Passage carrying the figure

“Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death worldwide, with about 2.6 million new cases and 1.9 million deaths estimated in 2024” (opens the source at this quote in a new tab)

Sung 2026, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

American cancer society 2026

Reference as the company lists it, press release, August 25, 2026

“American Cancer Society. Lung Cancer Statistics: How Common Is Lung Cancer? Accessed August 20, 2026.” (opens the source at this quote in a new tab)

Reference as the company lists it, website, Lung Cancer Overview

“Key Statistics for Lung Cancer. American Cancer Society (2025). Accessed June 24, 2025.” (opens the source at this quote in a new tab)

Reference as the company lists it, press release, August 6, 2024

“American Cancer Society: www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html. Accessed April 2024;” (opens the source at this quote in a new tab)

Reference as the company lists it, press release, October 31, 2023

“American Cancer Society: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html. Accessed October 2023” (opens the source at this quote in a new tab)

Passage carrying the figure, new US lung cancer cases in 2026

“The American Cancer Society’s estimates for lung cancer in the US for 2026 are:” (opens the source at this quote in a new tab)
“About 229,410 new cases of lung cancer (110,910 in men and 118,500 in women)” (opens the source at this quote in a new tab)

American Cancer Society (2026) Key Statistics for Lung Cancer, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Passage carrying the nearest figure, NSCLC share of lung cancer

“In general, about 13% of all lung cancers are SCLC, and about 77% are NSCLC.” (opens the source at this quote in a new tab)

American cancer society 2024

Reference as the company lists it

“American Cancer Society. What Is Lung Cancer? Types of Lung Cancer. Accessed August 20, 2026.” (opens the source at this quote in a new tab)

Passage carrying the figure

“About 80% to 85% of lung cancers are NSCLC.” (opens the source at this quote in a new tab)

American Cancer Society (2024) What Is Lung Cancer?, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

National cancer institute 2025

Reference as the company lists it

“National Cancer Institute. Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version. Accessed August 20, 2026.” (opens the source at this quote in a new tab)

Passage carrying the nearest figure

“In a set of 2,142 lung adenocarcinoma specimens from patients treated at Memorial Sloan Kettering Cancer Center, EGFR exon 19 deletions and L858R were found in 15% of tumors from former smokers” (opens the source at this quote in a new tab)

National Cancer Institute (2025) Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Midha 2015

Reference as the company lists it

“Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892-2911.” (opens the source at this quote in a new tab)

Passage carrying the nearest figure

“As expected, the Asia-Pacific NSCLC/ADC subgroup had the highest EGFR mutation frequency (47% [5958/12819; 87 studies; range 20%-76%])” (opens the source at this quote in a new tab)
“These data are similar to our findings in related patient populations: Asia-Pacific subgroup, 47%; and European subgroup, 15%.” (opens the source at this quote in a new tab)

Midha 2015, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

LUNGevity foundation 2024

Reference as the company lists it

“About EGFR-Positive Lung Cancer | Navigating EGFR (lungevity.org).” (opens the source at this quote in a new tab)

Passage carrying the nearest figure

“Approximately 15% of patients with NSCLC in the US and 35% of patients from East Asia have tumors with an EGFR driver mutation.” (opens the source at this quote in a new tab)

LUNGevity Foundation (2024) About EGFR-Positive Lung Cancer, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

LUNGevity foundation 2025

Reference as the company lists it

“Lung Cancer Statistics. LUNGevity (2025). Accessed June 24, 2025.” (opens the source at this quote in a new tab)

Passage carrying the nearest figure

“More than 229,000 people in the US will be diagnosed with lung cancer this year, with a new diagnosis every 2.3 minutes.” (opens the source at this quote in a new tab)

LUNGevity Foundation (2025) Lung Cancer Statistics, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

World health organization 2023

Reference as the company lists it

“World Health Organization: https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf. Accessed October 2023.” (opens the source at this quote in a new tab)

Passage carrying the figure

Not quoted: The cited address now redirects to the Global Cancer Observatory application and no longer serves the fact sheet the company accessed in October 2023; the fact sheet now published for Europe reports a later GLOBOCAN year.

International agency for research on cancer 2024

Reference as the company lists it

“World Health Organization: International Agency for Research on Cancer, Globocan data by country (UK, Spain, France, Italy, Germany);” (opens the source at this quote in a new tab)

Passage carrying the figure

Not quoted: The reference names a database queried by country, with no document, table, or address, so no passage can be identified.

Japan national cancer registry 2024

Reference as the company lists it

“Japan National Cancer Registry.” (opens the source at this quote in a new tab)

Passage carrying the figure

Not quoted: The reference names a registry, with no report, year, or address, so no passage can be identified.

National foundation for cancer research 2020

Reference as the company lists it

“National Foundation for Cancer Research. Small Cell Lung Cancer vs. Non-small Cell Lung Cancer: What's the Difference? (2020) Accessed June 24, 2025.” (opens the source at this quote in a new tab)

Passage carrying the nearest figure

“This type of lung cancer represents fewer than 20% of lung cancers and is typically caused by tobacco smoking.” (opens the source at this quote in a new tab)

National Foundation for Cancer Research (2020) Small Cell Lung Cancer vs. Non-small Cell Lung Cancer, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Overview

1Company statements of prevalence

Eligible population: Summit Therapeutics press release, January 2026

Incidence (all lung cancer): Summit Therapeutics press release, August 2026

Incidence (all lung cancer): Summit Therapeutics website, October 2026

Incidence (all lung cancer): Summit Therapeutics press release, October 2023

Incidence (all lung cancer in Europe): Summit Therapeutics press release, October 2023

Incidence (all lung cancer worldwide): Summit Therapeutics press release, August 2026

Number affected (all lung cancer): Summit Therapeutics press release, August 2024

Prevalence (share of non-squamous NSCLC with EGFR-sensitizing mutations): Summit Therapeutics press release, August 2024

Prevalence (share of non-squamous NSCLC with EGFR mutations): Summit Therapeutics press release, August 2026

Prevalence (share of all lung cancer that is NSCLC): Summit Therapeutics press release, August 2026

Prevalence (share of all lung cancer that is NSCLC): Summit Therapeutics website, October 2026

2Sources the company cites

Reference as the company lists it

Passage carrying the figure

Reference as the company lists it, press release, August 25, 2026

Reference as the company lists it, website, Lung Cancer Overview

Reference as the company lists it, press release, August 6, 2024

Reference as the company lists it, press release, October 31, 2023

Passage carrying the figure, new US lung cancer cases in 2026

Passage carrying the nearest figure, NSCLC share of lung cancer

Reference as the company lists it

Passage carrying the figure

Reference as the company lists it

Passage carrying the nearest figure

Reference as the company lists it

Passage carrying the nearest figure

Reference as the company lists it

Passage carrying the nearest figure

Reference as the company lists it

Passage carrying the nearest figure

Reference as the company lists it

Passage carrying the figure

Reference as the company lists it

Passage carrying the figure

Reference as the company lists it

Passage carrying the figure

Reference as the company lists it

Passage carrying the nearest figure

3References

Company statements of prevalence

Sources the company cites

References